Jeremy McComish1,2, Joy Mundy1, Tom Sullivan3, Susanna M Proudman4,5, Pravin Hissaria1,6. 1. Division of Human Immunology, SA Pathology (IMVS), Adelaide, South Australia, Australia. 2. Immunology and Allergy Unit, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia. 3. Discipline of Public Health, University of Adelaide, Adelaide, South Australia, Australia. 4. Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. 5. The University of Adelaide, Adelaide, South Australia, Australia. 6. Clinical Immunology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Abstract
OBJECTIVE: To assess variation in peripheral blood B lymphocyte subsets in rheumatoid arthritis (RA). METHODS: B lymphocyte subsets in disease-modifying anti-rheumatic drug (DMARD)-naïve patients with RA (n = 30), patients with RA treated with DMARDs (n = 73) and healthy controls (n = 46) were analyzed by flow cytometry. Total B cells, total memory B cells, immunoglobulin M (IgM) memory B cells, switched memory B cells, non-switched memory B cells, CD21lo B cells, transitional B cells and plasmablasts were measured. Correlation with clinical and laboratory parameters was performed. RESULTS: Total memory B cells, IgM memory B cells and non-switched memory B cells were reduced in RA patients at diagnosis compared to controls (P < 0.05). In patients with treated RA, there was a further reduction of total B cells, CD21lo cells, transitional B cells and plasmablasts, compared to controls (P < 0.05). The reduction in absolute numbers of total B cells, switched memory B cells, CD21lo cells, transitional B cells and plasmablasts in treated RA patients was significant (P < 0.05) even when compared to the DMARD-naïve patients. Only treatment responders (Disease Activity Score < 3.2) had reduced total B cells and absolute numbers of switched and IgM memory B cells (P < 0.05). In patients requiring leflunomide, total memory B cells, IgM memory B cells, non-switched memory B cells and absolute numbers of switched memory B cells were reduced compared with the remainder of the patient group (P < 0.05). CONCLUSION: There is reduction of various B cell subsets in RA patients at diagnosis. Treatment with DMARDs leads to further reduction in additional B cell subsets without correction of the abnormalities. Reduction in individual subsets may predict RA patients requiring more intensive therapy.
OBJECTIVE: To assess variation in peripheral blood B lymphocyte subsets in rheumatoid arthritis (RA). METHODS: B lymphocyte subsets in disease-modifying anti-rheumatic drug (DMARD)-naïve patients with RA (n = 30), patients with RA treated with DMARDs (n = 73) and healthy controls (n = 46) were analyzed by flow cytometry. Total B cells, total memory B cells, immunoglobulin M (IgM) memory B cells, switched memory B cells, non-switched memory B cells, CD21lo B cells, transitional B cells and plasmablasts were measured. Correlation with clinical and laboratory parameters was performed. RESULTS: Total memory B cells, IgM memory B cells and non-switched memory B cells were reduced in RApatients at diagnosis compared to controls (P < 0.05). In patients with treated RA, there was a further reduction of total B cells, CD21lo cells, transitional B cells and plasmablasts, compared to controls (P < 0.05). The reduction in absolute numbers of total B cells, switched memory B cells, CD21lo cells, transitional B cells and plasmablasts in treated RApatients was significant (P < 0.05) even when compared to the DMARD-naïve patients. Only treatment responders (Disease Activity Score < 3.2) had reduced total B cells and absolute numbers of switched and IgM memory B cells (P < 0.05). In patients requiring leflunomide, total memory B cells, IgM memory B cells, non-switched memory B cells and absolute numbers of switched memory B cells were reduced compared with the remainder of the patient group (P < 0.05). CONCLUSION: There is reduction of various B cell subsets in RApatients at diagnosis. Treatment with DMARDs leads to further reduction in additional B cell subsets without correction of the abnormalities. Reduction in individual subsets may predict RApatients requiring more intensive therapy.
Authors: Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667
Authors: H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño Journal: Clin Exp Immunol Date: 2021-03-02 Impact factor: 4.330
Authors: Estefanía R Zacca; Luisina I Onofrio; Cristina D V Acosta; Paola V Ferrero; Sergio M Alonso; María C Ramello; Eduardo Mussano; Laura Onetti; Isaac I Cadile; Maria I Stancich; Maria C Taboada Bonfanti; Carolina L Montes; Eva V Acosta Rodríguez; Adriana Gruppi Journal: Front Immunol Date: 2018-10-01 Impact factor: 7.561
Authors: Emily S J Edwards; Julian J Bosco; Pei M Aui; Robert G Stirling; Paul U Cameron; Josh Chatelier; Fiona Hore-Lacy; Robyn E O'Hehir; Menno C van Zelm Journal: Front Immunol Date: 2019-11-15 Impact factor: 7.561
Authors: E R Zacca; M C Amezcua Vesely; P V Ferrero; C D V Acosta; N E Ponce; S N Bossio; E Mussano; L Onetti; I Cadile; E V Acosta Rodríguez; C L Montes; A Gruppi Journal: J Mol Biol Date: 2020-10-22 Impact factor: 6.151
Authors: Joyce Lübbers; Marian H van Beers-Tas; Saskia Vosslamber; Samina A Turk; Sander de Ridder; Elise Mantel; John G Wesseling; Martine Reijm; Ingrid M van Hoogstraten; Johannes W Bijlsma; Dirkjan van Schaardenburg; Hetty J Bontkes; Cornelis L Verweij Journal: Arthritis Res Ther Date: 2016-09-14 Impact factor: 5.156
Authors: Peter Heukels; Odilia B J Corneth; Denise van Uden; Jennifer A C van Hulst; Leon M van den Toorn; Annemien E van den Bosch; Marlies S Wijsenbeek; Karin A Boomars; Mirjam Kool; Rudi W Hendriks Journal: Thorax Date: 2021-05-07 Impact factor: 9.139